Advertisement
Screener

JASPER THERAPEUTICS, INC. (JSPR) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount

1.1 / 5 stars · 8/38 Roast Me

JASPER THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount

JASPER THERAPEUTICS, INC. (JSPR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $26.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-02-28

  • JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $26.00K.
  • JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was -$38.00K.
  • JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was -$108.00K, a 117.06% decline from fiscal 2021.
  • JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $633.00K, a 174.03% increase from fiscal 2020.
Period endEffective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month
2024-12-31$26.00K
10-K · filed 2025-02-28
2023-12-31-$38.00K
10-K · filed 2025-02-28
2022-12-31-$108.00K
10-K · filed 2024-03-05
2021-12-31$633.00K
10-K · filed 2023-03-08
2020-12-31$231.00K
10-K · filed 2022-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
IN8BIO, INC. (INAB)United States$0.012B-0.76
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
CEL SCI CORP (CVM)United States$0.030B-0.81